|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.0389 USD | -5.12% |
|
-2.75% | +49.62% |
| 05-18 | Adaptimmune Therapeutics plc Reports Earnings Results for the Full Year Ended December 31, 2025 | CI |
| 11-17 | Adaptimmune Therapeutics plc Announces CEO Changes | CI |
| Market Cap | 10.31M 9.04M 8.33M 7.8M 14.63M 973M 14.93M 100M 38.76M 481M 38.72M 37.87M 1.67B | P/E 2024 |
-1.8x | P/E 2025 | 0.33x |
|---|---|---|---|---|---|
| Enterprise Value | -1.56M -1.37M -1.26M -1.18M -2.21M -147M -2.26M -15.14M -5.86M -72.66M -5.85M -5.72M -252M | EV / Sales 2024 |
0.34x | EV / Sales 2025 | -0.84x |
| Free-Float |
14.03% | Yield 2024 * |
-
| Yield 2025 | - |
| 1 day | -5.12% | ||
| 1 week | -2.75% | ||
| Current month | +537.70% | ||
| 1 month | +224.17% | ||
| 3 months | +285.15% | ||
| 6 months | +39.43% | ||
| Current year | +49.62% |
| 1 week | 0.02 |  | 0.04 |
| 1 month | 0.01 | | 0.04 |
| Current year | 0 | | 0.04 |
| 1 year | 0 | | 0.36 |
| 3 years | 0 | | 2.05 |
| 5 years | 0 | | 6.86 |
| 10 years | 0 | | 14.62 |
| Manager | Title | Age | Since |
|---|---|---|---|
Christopher Hill
CEO | Chief Executive Officer | 46 | 2025-11-13 |
Juli P. Miller
IRC | Investor Relations Contact | - | 2016-07-31 |
Phil Bassett
PRN | Corporate Officer/Principal | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
Lawrence Alleva
CHM | Chairman | 76 | 2025-11-13 |
Garry Menzel
BRD | Director/Board Member | 61 | 2023-05-31 |
Christopher Hill
BRD | Director/Board Member | 46 | 2025-11-13 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 25-09-01 | Sell | Chief Financial Officer | 96,000 | 0.0060% | ||
| 25-08-27 | Sell | Compliance Officer | 207,000 | 0.0130% | ||
| 25-08-14 | NEA Management Co. LLC
| Sell | Company | 19,500,000 | 7.3571% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -5.12% | -2.75% | -84.62% | -95.91% | 10.87M | |
| +2.06% | +3.76% | +21.64% | -18.83% | 63.09B | |
| +0.74% | +3.73% | +53.05% | +208.91% | 55.61B | |
| -3.10% | +34.30% | +34.30% | +34.30% | 41.64B | |
| -2.36% | +6.28% | -51.83% | -59.27% | 38.98B | |
| +6.97% | +9.89% | +69.69% | -24.07% | 29.82B | |
| +12.59% | +5.18% | +150.45% | -43.23% | 23.71B | |
| +5.78% | +15.81% | +68.39% | +82.15% | 21.48B | |
| -1.25% | -1.31% | -8.80% | +146.80% | 16.87B | |
| -0.81% | +5.91% | +68.18% | +121.16% | 16.74B | |
| Average | +0.26% | +3.21% | +32.05% | +35.20% | 30.8B | |
| Weighted average by Cap. | +0.78% | +3.29% | +38.41% | +45.70% |
| 2024 | 2025 | |
|---|---|---|
| Net sales | 178M 156M 144M 135M 253M 16.79B 258M 1.73B 669M 8.3B 669M 654M 28.78B | 5.92M 5.19M 4.79M 4.48M 8.41M 559M 8.58M 57.55M 22.27M 276M 22.24M 21.76M 958M |
| Net income | -70.81M -62.09M -57.23M -53.58M -100M -6.68B -103M -688M -266M -3.3B -266M -260M -11.45B | 25.21M 22.1M 20.37M 19.07M 35.76M 2.38B 36.51M 245M 94.74M 1.18B 94.65M 92.58M 4.07B |
| Net Debt | -77.4M -67.86M -62.55M -58.56M -110M -7.3B -112M -752M -291M -3.61B -291M -284M -12.51B | -11.87M -10.41M -9.59M -8.98M -16.84M -1.12B -17.19M -115M -44.61M -553M -44.57M -43.59M -1.92B |
Employees
272
Sector
Pharmaceuticals
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-06-26 | US$0.0389 | -5.12% | 501,785 |
| 26-06-25 | US$0.0410 | +13.89% | 676,443 |
| 26-06-24 | US$0.0360 | +6.82% | 452,328 |
| 26-06-23 | US$0.0337 | -15.75% | 137,766 |
| 26-06-22 | US$0.0400 | 0.00% | 241,604 |
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- ADAPY Stock
Select your edition
All financial news and data tailored to specific country editions
